CD80
- Known as:
- CD80
- Catalog number:
- 11-287-C025
- Product Quantity:
- 0.025 mg
- Category:
- -
- Supplier:
- Exbio
- Gene target:
- CD80
Related genes to: CD80
- Gene:
- CD80 NIH gene
- Name:
- CD80 molecule
- Previous symbol:
- CD28LG, CD28LG1
- Synonyms:
- B7.1, B7-1
- Chromosome:
- 3q13.33
- Locus Type:
- gene with protein product
- Date approved:
- 1993-12-14
- Date modifiied:
- 2016-10-05
Related products to: CD80
Activation B7-1 antigen,B7,B7,Cd80,Mouse,Mus musculus,T-lymphocyte activation antigen CD80Activation B7-1 antigen,B7,BB1,CD28LG,CD28LG1,CD80,CTLA-4 counter-receptor B7.1,Homo sapiens,Human,LAB7,T-lymphocyte activation antigen CD80Activation B7-1 antigen,CD80,Oryctolagus cuniculus,Rabbit,T-lymphocyte activation antigen CD80anti-CD80anti-CD80anti-CD80anti-CD80anti-CD80anti-CD80 (1G1)anti-CD80 (3D7)anti-CD80 (3E10)anti-CD80 (4A4)anti-CD80 (1G1)anti-CD80 (1G1) type: Primary antibodies host: Mouseanti-CD80 (2A2) Related articles to: CD80
- Synovial plasma cell infiltration predicts inadequate response to adalimumab in patients with rheumatoid arthritis (RA), yet the cellular and molecular mechanisms underlying this association remain unclear. This study aimed to dissect the functional heterogeneity of synovial plasma cells between adalimumab responders and non-responders at single-cell resolution, and to identify the molecular pathways driving treatment resistance. - Source: PubMed
Publication date: 2026/09/04
Li JianbinJiang HouhuiWu DengfengXiong ZhenfangPeng YilinZhao JunLiu PengchengWu Rui - Prolonged antibiotic use has led to increased bacterial resistance, making antibacterial peptides a promising alternative. We previously identified that the anti-apoptotic lncRNA-803 could encode short peptides, though their functions were unknown. - Source: PubMed
Publication date: 2026/08/20
Han ShuoJiang JunxiDuan WeiLuo LinDu NingWu WanxiongAn MingweiAilibieke GulaliyaAlgharib Samah AttiaLiu JunfengLuo Wanhe - Obesity represents a global health crisis characterized by chronic adipose tissue (AT) inflammation (metaflammation) driven by pro-inflammatory M1 macrophage (MΦ) polarization, adipocyte hypertrophy, and impaired thermogenic capacity of white adipose tissue (WAT). While interleukin-4 (IL-4) potently induces M2 MΦ polarization, its clinical translation is limited by poor stability, rapid clearance, and off-target effects. Here, we engineered lipid nanoparticles (IL-4/LNP) via simple, robust thin-film hydration and extrusion to enable sustained IL-4 delivery to MΦs in inflamed AT. In vitro, IL-4/LNP achieved >70% encapsulation efficiency, a uniform ∼150 nm size, and superior M1 to M2 MΦ reprogramming compared with free IL-4, as evidenced by CD206 upregulation, reduced CD80/CD40 expression, and attenuated TNF-α/IL-6 secretion in LPS-stimulated MΦ. In adipocyte-mimicking cells (3T3-L1)-MΦ co-cultures representing white and brown adipose tissue (BAT), paracrine signaling from IL-4/LNP-polarized M2 MΦs drove a profound reduction in lipid droplets (LDs) and beiging, with decreased Feret diameter and integrated optical density. Using a high-fat diet-induced obese mouse model, localized inguinal/visceral AT injections blunted weight gain by ∼10%, induced multilocular beige-like adipocytes across depots, upregulated thermogenic genes (Ucp1 and Pgc1α), downregulated inflammatory markers (IL-6), and improved hepatic steatosis without systemic toxicity. These findings establish IL-4/LNP as a safe, multifunctional platform that links MΦ immunomodulation and adipose browning in obesity therapy. STATEMENT OF SIGNIFICANCE: This study establishes IL-4-loaded lipid nanoparticles (IL-4/LNPs) as a nanomedicine platform that targets the immunometabolic roots of obesity by reprogramming adipose tissue macrophages and promoting white fat browning. IL-4/LNPs are produced by a simple, scalable thin-film hydration-extrusion method, yielding ∼150 nm particles with ∼73% encapsulation, suitable for local adipose delivery. In vitro, the NPs outperform free IL-4 by enhancing M2 polarization, driving paracrine adipocyte remodeling, and reducing lipid burden in 3T3-L1 co-cultures. In high-fat diet-obese mice, depot-specific IL-4/LNP injections limit weight gain, induce adipocyte beiging, improve hepatic steatosis, and reduce systemic inflammation without detectable toxicity, supporting IL-4/LNPs as a translatable cytokine nanotherapy for metaflammatory obesity. - Source: PubMed
Publication date: 2026/09/03
Mohaghegh NedaBalajam Narges ZargarKraemer NickMarx TaliaSawant ShraddhaDigholkar Gargi YO'Raw AlieshaShen XilingKang HeeminPearson Ryan MNajafabadi Alireza Hassani - is a major opportunistic pathogen of ruminants that causes foot rot and liver abscesses and contributes to substantial economic losses. Current vaccines provide limited protection. Here, we prepared and evaluated outer membrane vesicles (OMVs)-based vaccine candidate derived from . OMVs were purified by density-gradient centrifugation and were characterized for morphology, composition, and immunological activity. The purified OMVs showed intact vesicle structure and a uniform particle size distribution and contained virulence-associated antigens and pathogen-associated molecular patterns. OMVs were rapidly taken up by dendritic cells and promoted dendritic cell maturation, as indicated by activation of PI3K/AKT signaling and increased expression of MHC I, MHC II, CD80, and CD86. imaging showed persistent fluorescence at the injection site and signal accumulation in draining lymph nodes and the spleen. In mice, OMVs immunization induced high titers of antigen-specific IgG and elicited a Th1-biased cellular immune response. In a lethal challenge, OMVs immunization achieved 100% survival, significantly reduced liver bacterial loads, and alleviated inflammatory and necrotic liver lesions. In sheep, OMVs immunization also induced progressively increased antigen-specific IgG and a predominantly Th1 type cellular immune response, supporting strong immunogenicity in a natural host. Together, these results support OMVs as a promising vaccine candidate containing multiple native antigens for the prevention and control of - associated diseases in ruminants. - Source: PubMed
Publication date: 2026/09/01
Zhao PengyuJiang JianchengYang NingLiu RongqiJiang KaiBi LanHe XianjingGuo Donghua - Targeted therapies with monoclonal antibodies provide cancer patients with better prognosis and disease-free survival. The blockade of immune checkpoints, including programmed cell death protein-1 (PD-1) and its ligand PD-L1, with monoclonal antibodies may boost immune responses against tumors and is regarded as an effective strategy in cancer immunotherapy. We describe the generation of anti-PD-L1 monoclonal antibodies with high affinity and specificity, and we assess their potential for therapeutic use in cancer. - Source: PubMed
Publication date: 2026/05/31
Ersezen NurşahŞeker MaideAysan ArzuAkdoğan DurmuşAvci Mehmet EnderPekmezci Aslı KurdenUzunlar Sibel KalyoncuInan MehmetYağci Tamer